IRLAB Therapeutics AB (publ) (STO:IRLAB.A)

Market Cap	378.12M
Revenue (ttm)	102.69M
Net Income (ttm)	-78.08M
Shares Out	51.87M
EPS (ttm)	-1.51
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	42,860
Average Volume	21,178
Open	7.31
Previous Close	7.40
Day's Range	7.10 - 7.40
52-Week Range	4.25 - 18.50
Beta	0.44
RSI	49.93
Earnings Date	Apr 21, 2025

About IRLAB Therapeutics AB

IRLAB Therapeutics AB (publ) discovers and develops drugs for the treatment of Parkinson’s disease and other CNS disorders. The company develops Mesdopetam that is in phase IIb clinical studies for the treatment of levodopa-induced dyskinesia; and Pirepemat, which is in phase IIb clinical trial indicated for the treatment of falls frequency, postural dysfunction, cognitive function, and symptoms of Parkinson’s disease. Its preclinical stage products include IRL942 research programs for the treatment of cognitive deficits in Parkinson’s and othe...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 31
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: IRLAB.A

Financial Performance

In 2024, IRLAB Therapeutics AB's revenue was 94.63 million, an increase of 1566.57% compared to the previous year's 5.68 million. Losses were -83.13 million, -53.26% less than in 2023.